The Latest
The Berlin Patient, the First Person Ever Cured of HIV, on Taking PrEP: "I Want a Full Sexual Life"
Timothy Ray Brown, known as "the Berlin patient," has begun taking PrEP to make sure he doesn't have to deal with an HIV diagnosis -- again.
This Week in HIV Research: U=U Grows Ever Stronger
Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.
FDA Approves Descovy for PrEP, but Only for Cisgender Men and Transgender Women
The FDA approved the fixed-dose combination of emtricitabine and tenofovir alafenamide for PrEP, but advocates hope to see more research on the HIV prevention drug's efficacy for receptive vaginal sex for cisgender women and transgender men.
This Week in HIV Research: The Reality of Disparity
Sept. 26, 2019: Racial disparities in the PrEP continuum; HIV and ocular syphilis; Kaposi sarcoma among people with well-suppressed HIV; modifiable risk factors in the management of chronic kidney disease.
This Week in HIV Research: Every Prescription Can Use a Good Steward
Sept. 19, 2019: HIV antiretroviral stewardship plans in hospitals can save money -- and lives; demographic correlates of PrEP interruption; HIV and atrial fibrillation risk; cytopenias common, despite viral suppression.
This Week in HIV Research: New Keys to the Care Continuum
Sept. 12, 2019: Better virologic outcomes at coordinated walk-in facilities offering incentives; same-day PrEP initiation at STD clinics; U=U and "low drug regimens"; adherence trends among perinatally infected adolescents.
Four PrEP Studies Address Challenges and Best Practices for Uptake and Retention
Four recent studies in JAIDS chiefly focused on PrEP provision to cisgender women and gay and bisexual men.
This Week in HIV Research: Sex, Drugs, and Broken Bones
Aug. 8, 2019: Casual sex partners increase among U.S. MSM; why some MSM undervalue PrEP; proteinuria prevalence and fracture risk; cannabis, cocaine, and inflammation in people living with HIV.
DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF
But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.
This Week in HIV Research: When STIs Flock Together
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.